Xiaobing Liu

Dr. Xiaobing Liu

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 July 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
XLXiaobing Liu
Xiaobing Liu
XLXin Liu
Xin Liu
YWYuqi Wu
Yuqi Wu
ZFZhenqiang Fang
Zhenqiang Fang
QWQingjian Wu
Qingjian Wu
LLLongkun Li
Longkun Li
Background/Aims: Chemoresistance is largely responsible for relapses of bladder cancer during clinical therapy. However, the molecular mechanisms involved in the chemoresistance of bladder cancer are unclear. Growing evidence supports the theory that microRNAs (miRNAs) play an important role in chemotherapeutic drug resistance because they are downregulated in many malignancies that have been implicated in the regulation of diverse processes in cancer cells. More specifically, the extent and precise mechanism of the involvement of miR-34as in chemoresistance to epirubicin (EPI) in the treatment of bladder cancer remains unclear. Methods: In this study, real-time quantitative polymerase chain reaction (PCR) was used to analyze the expression of miR-34a in bladder cancer cell line BIU87 and its EPI chemoresistant cell line BIU87/ADR. The miR-34a profiles in bladder cancer tissues were obtained from The Cancer Genome Atlas database. The effect of miR-34a on chemosensitivity was evaluated by cell viability assays, colony formation assays, and in vivo experimentation. Apoptosis and the cell cycle were examined by flow cytometry. A luciferase reporter assay was used to assess the target genes of miR-34a. Western blot and qPCR were used to analyze the expression of target proteins and downstream molecules. Results: The downregulation of miR-34a in bladder cancer serves as an independent predictor of reduced patient survival. The CCK-8 assay showed that miR-34a overexpression resulted in increased sensitivity to EPI, while miR-34a downregulation resulted in chemoresistance to EPI in vitro. Moreover, it was found that miR-34a increased the sensitivity of BIU87/ADR cells to chemotherapy in vivo. The luciferase reporter assay ascertained that TCF1 and LEF1 are direct target genes of miR-34a. It was found that miR-34a increased chemosensitivity in BIU87/ADR cells by inhibiting the TCF1/LEF1 axis. Conclusions: The results of this study indicate that miR-34a contributes to the chemosensitivity of BIU87/ADR by inhibiting the TCF1/LEF1 axis. Consequently, miR-34a is a determinant of BIU87 chemosensitivity and may therefore serve as a potential therapeutic target in bladder cancer treatment.

5 May 2018 in Cellular Physiology and Biochemistry
Verified
Journal Article
Open access
PDF file
XLXiaobing Liu
Xiaobing Liu
DZDangling Zhang
Dangling Zhang
YHYaxing Hao
Yaxing Hao
QLQian Liu
Qian Liu
YWYuqi Wu
Yuqi Wu
LLLongkun Li
Longkun Li
Background/Aims: Cyanidin is an anthocyanin found in many foods. Although its variable antioxidant levels are well-documented, little is known about its effects on renal cell carcinoma (RCC) tumorigenesis. This study, therefore, investigated the effects of cyanidin on the proliferation, migration, and invasion of renal cell carcinoma lines and demonstrated, for the first time, significant inhibitory effects of cyanidin on RCC tumorigenesis. Methods: RCC cells were treated with different doses of cyanidin and the effects were tested by Cell Counting Kit-8 reagent, clone formation assay, transwell assay, and flow cytometry. Moreover, the cyanidin-mediated mechanism that curtailed tumorigenesis was analyzed by RNA sequencing (RNA-seq). Sequencing data from The Cancer Genome Atlas (TCGA) were used to compare the expression of both early growth response protein 1 (EGR1) and selenoprotein W (SEPW1) in RCC and tumor-free adjacent normal tissue samples. Real-time PCR (RT-PCR) and/or western blot were used to assess the expression of E-cadherin, cleaved-caspase3, Bcl2, p62, and ATG4. Results: We found significantly greater induction of cell-cycle arrest, apoptosis, and suppression of RCC cell invasion and migration at concentrations of 25 µM and 100 µM than at a concentration of 50 µM. It was also discovered, first through RNA-seq then confirmed by RT-PCR, that cyanidin (100 µM) inhibited RCC carcinogenesis through EGR1 and SEPW1. TCGA data indicated that the expression level of EGR1 was lower and that of SEPW1 was higher in RCC tumor tissue than in normal tissues. Moreover, western blot and/or RT-PCR indicated that cleaved-caspase3 was enhanced and E-cadherin was inhibited by cyanidin treatment. Furthermore, western blot and RT-PCR also showed regulation of p62 and ATG4, which are associated with autophagy. Cyanidin in vivo significantly inhibited the growth of xenografts in nude mice. Conclusions: The results of this study showed the therapeutic potential of cyanidin for the treatment of RCC and the prevention of recurrence and metastasis.

1 February 2018
Verified
Book Chapter
Closed access
PDF file
YHYaxing Hao
Yaxing Hao
ZLZhirong Li
Zhirong Li
YWYifei Wang
Yifei Wang
XLXiaobing Liu
Xiaobing Liu
LYLilin Ye
Lilin Ye

7 October 2025 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
QLQuan xing Liu
Quan xing Liu
LJLi Jiang
Li Jiang
KWKai Wang
Kai Wang
JDJi-Gang Dai
Ji-Gang Dai
XLXiaobing Liu
Xiaobing Liu
Lung cancer remains the leading cause of cancer mortality, hindered by drug resistance, limited targeting, and low immunotherapy response. This review presents biomimetic superparamagnetic iron-oxide nanoparticles (SPIONs) as a next-generation theranostic platform. By cloaking SPIONs with cell membranes—macrophage, neutrophil, or cancer cell—we endow them with biological targeting, immune evasion, and deep lung penetration. Coupled with magnetic field-guided retention and real-time imaging, these systems enable precision hyperthermia, on-demand drug release, and immune microenvironment reprogramming. We critically compare membrane types, outline translational challenges, and propose a regulatory-aligned safety framework. This biomimetic strategy offers a dual diagnostic–therapeutic solution for lung cancer and potentially other solid tumors.

1 April 2025 in Medical Oncology
Verified
Journal Article
Closed access
PDF file
JWJingsi Wang
Jingsi Wang
XDXufeng Deng
Xufeng Deng
MLManyuan Li
Manyuan Li
XLXiaobing Liu
Xiaobing Liu
QLQuan xing Liu
Quan xing Liu

1 April 2026 in Journal of Thoracic Disease
Verified
Journal Article
Open access
PDF file
RWRenyu Wang
Renyu Wang
PDPeng Dai
Peng Dai
XDXufeng Deng
Xufeng Deng
XLXiaobing Liu
Xiaobing Liu
ZYZubin Yu
Zubin Yu
QLQuan xing Liu
Quan xing Liu
Background: Thymoma is an uncommon cancer of the thymus and postoperative radiotherapy (PORT) is often considered for selected patients with high-risk or locally advanced thymoma after resection. The effect of PORT on overall survival (OS) and cardiac-specific mortality in patients with thymoma is not well understood. The purpose of this study was to assess the impact of PORT on OS and cardiac-specific mortality in resected thymoma patients. Methods: We analyzed the data from Surveillance, Epidemiology, and End Results (SEER) database to identify patients with thymoma who had a cancer-directed operation alone or with PORT. A propensity score matching (PSM) was employed to adjust for imbalances in two groups. OS was analysed with Kaplan-Meier. Comparison of cumulative incidence curves for cardiac-specific mortality between the groups was performed using Fine and Gray’s model. Results: There was a total of 3,434 patients with thymoma. After 1:1 matching, 1,078 patients remained in each group and PORT was independently correlated with better survival (P=0.004). The 5-year OS was 88.2% for the PORT group and 84.1% for the non-PORT group. With respect to cardiac-specific mortality, the cumulative incidence at 15 years for PORT vs. non-PORT patients following matching was PORT, 8.3% and non-PORT, 6.1%, with no difference in Gray’s test (P=0.44). In a multivariable competing-risk model, PORT was not significantly associated with cardiac-specific mortality in a multivariable competing-risk analysis [hazard ratio (HR) =1.25, 95% confidence interval (CI): 0.84–1.86; P=0.28]. Conclusions: PORT was associated with improved long-term survival. No statistically significant increase in cardiac-specific mortality was observed; however, a moderate increase in risk cannot be excluded given the limited number of cardiac events. These findings suggest that PORT remains an appropriate part of thymoma management.